A second space age spanning omics, platforms and medicine across orbits
- PMID: 38862027
- PMCID: PMC12366838
- DOI: 10.1038/s41586-024-07586-8
A second space age spanning omics, platforms and medicine across orbits
Abstract
The recent acceleration of commercial, private and multi-national spaceflight has created an unprecedented level of activity in low Earth orbit, concomitant with the largest-ever number of crewed missions entering space and preparations for exploration-class (lasting longer than one year) missions. Such rapid advancement into space from many new companies, countries and space-related entities has enabled a 'second space age'. This era is also poised to leverage, for the first time, modern tools and methods of molecular biology and precision medicine, thus enabling precision aerospace medicine for the crews. The applications of these biomedical technologies and algorithms are diverse, and encompass multi-omic, single-cell and spatial biology tools to investigate human and microbial responses to spaceflight. Additionally, they extend to the development of new imaging techniques, real-time cognitive assessments, physiological monitoring and personalized risk profiles tailored for astronauts. Furthermore, these technologies enable advancements in pharmacogenomics, as well as the identification of novel spaceflight biomarkers and the development of corresponding countermeasures. In this Perspective, we highlight some of the recent biomedical research from the National Aeronautics and Space Administration, Japan Aerospace Exploration Agency, European Space Agency and other space agencies, and detail the entrance of the commercial spaceflight sector (including SpaceX, Blue Origin, Axiom and Sierra Space) into aerospace medicine and space biology, the first aerospace medicine biobank, and various upcoming missions that will utilize these tools to ensure a permanent human presence beyond low Earth orbit, venturing out to other planets and moons.
© 2024. Springer Nature Limited.
Conflict of interest statement
Competing interests
CEM is a co-Founder of Cosmica Biosciences. SMB is a co-founder and Scientific Advisory Board member of KromaTiD, Inc.
Figures



References
-
- Whiting M Valentina Tereshkova and Sally Ride - Women Space Pioneers. NASA; http://www.nasa.gov/mediacast/valentina-tereshkova-and-sally-ride-women-... (2018).
-
-
Kim J, et al. Single-cell multi-ome and immune profiles of the Inspiration4 crew reveal cell-type and sex-specific responses to spaceflight. Nat Commun (in press).
The SpaceX Inspiration4 mission enabled state-of-the-art, single-cell multi-omics analysis of four astronauts, revealing that spaceflight-induced changes in gene expression, chromatin accessibility, and immune cell proportions, particularly in non-classical monocytes and NK cells, largely revert to normal within a few months post-flight, providing crucial data for future space missions and countermeasure development.
-
-
- Mathyk B et al. Spaceflight alters insulin and estrogen signaling pathways. Comms Bio. (2024) doi: 10.1038/s42003-023-05213-2. - DOI
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources